• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Alnara Pharmaceuticals

edit

Alnara Pharmaceuticals, Inc. is dedicated to developing novel protein therapeutics for the treatment of metabolic diseases. The company’s innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream.

Recent Milestones

edit

• 
  Alnara Pharmaceuticals was acquired by Eli Lilly. (7/2/10)
  Posted 7/4/10 at 6:47pm via fiercebiotech.com
• 
  Alnara Pharmaceuticals received $35M in Series B funding. (1/28/10)
  Posted 1/28/10 at 2:34pm via fiercebiotech.com
• 
  Alnara Pharmaceuticals received $20M in Series A funding. (10/30/08)
  Posted 6/25/09 at 10:16am via xconomy.com
• 
  Alnara Pharmaceuticals added John Ledoux as Director of Finance.
  Posted 5/24/13 at 2:24am

Videos

Screenshots

edit

Above: Alnara Pharmaceuticals Screenshot -- #1
Uploaded: 6/25/09

Sources

1. Lilly buys Alnara for undisclosed sum (fiercebiotech.com) [edit]
2. Alnara Pharmaceuticals Inc Obtains $20,000,000 Series A Round (xconomy.com) [edit]
3. http://www.fiercebiotech.com/story/alnara-grabs-35m-vc-cash-it-aims-nda/2010-01-28?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB0 (fiercebiotech.com) [edit]